Abstract 699P
Background
As COVID-19 will likely became an epidemic disease, vaccination planning will be crucial for LS-mLC receiving anti-cancer therapy (ACT) in order to prolong effective immunity
Methods
According to the timing of BD and Sars-Cov2 infection (Cov-I) during oncological history, LC pts were allocated in three cohorts: A) Cov-I before PV or third BD; B) uninfected who completed PV during ACT; C) uninfected LC who had completed PV before cancer diagnosis and will receive BD after stating of ACT. As control cohorts, we included other cancer patients (mOC pts) who had completed PV and were candidate to BD during myelosuppressive (cohort D) or not-myelosuppressive (cohort E) ACT. The primary endpoints were seroprevalence of IgG Anti-spike-RBD (anti-S IgG) at two pre-defined time-points (T1: +30-90 days after BD; T2: + 6 months +/- 4 weeks after BD). As exploratory endpoint, we compared median pre-vaccination value of four cytokines (IL-6, IL-2R, TNF-α, IL-10) with post-BD values in immunotherapy-treated pts (IT-pts)
Results
Between October 2021 and February 2022, 113 LS-mLC patients were assigned in cohort A (20 pts), in cohort B (61 pts) or in cohort C (32 pts); 55 LS-mOC patients were allocated in cohort D (25 pts) and in cohort E (30 pts). Throughout the Omicron variant spread, 40 pts (24%) experienced Cov-I before T2 evaluation. Anti-S IgG qualitative seropositivity rate was 100% at T1 and 98.8% at T2. After 6-months FU, hybrid immunization (Cov-I before or after BD), was associated with higher median anti-S IgG trier compared to vaccine alone-induced immunity (p = <0.0001). In uninfected pts, median anti-S IgG titre was significantly lower in IT-treated patients compared to non-IT treated patients (p = 0.02); no difference was found when comparing myelosuppressive or not ACT. Among 68 IT-pts, 5 pts (7.3%) showed significant increase (≥ 1.5 fold) of at least two cytokines in post-BD samples, without reporting ir-AE
Conclusions
Administration BDs of COVID-19 mRNA vaccine in LS-mLC pts resulted effective and safe. In IT-pts without recent Cov-I, additional BDs should be considered to prolong serological immunity
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fondazione Policlinico Universitario A Gemelli-IRCCS.
Funding
Grant Award: Vaccinazione Anti-COVID-19 Nei Pazienti Oncologici, Sponsor: AIOM (Associazione Italiana di Oncologia Medica)/FICOG (Federation of Italian Cooperative Oncology Groups).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
689P - DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) I/IIa study
Presenter: Omkar Marathe
Session: Poster session 17
690P - Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase I/II study
Presenter: Manish R Patel
Session: Poster session 17
691P - Efficacy of ABBV-400 monotherapy in patients with MET gene amplified advanced solid tumors
Presenter: John Strickler
Session: Poster session 17
692P - First-in-human study of ELU001, a targeted nanoparticle drug conjugate, in subjects with folate receptor α (FRα) overexpressing solid tumors
Presenter: Wen wee Ma
Session: Poster session 17
693P - Preclinical activity of HLX43, a PD-L1-targeting ADC, in multiple PD-1/PD-L1 refractory/resistant models
Presenter: Yongqiang Shan
Session: Poster session 17
694P - Full efficacy analysis of phase I/II trial investigating bexmarilimab, a novel macrophage-guided immunotherapy in refractory solid tumors
Presenter: Petri Bono
Session: Poster session 17
695P - A phase I/Ib study evaluating the safety and tolerability of NIZ985 alone and in combination with spartalizumab (anti–PD-1) in patients (pts) with solid tumors or lymphoma
Presenter: Elena Garralda
Session: Poster session 17
696P - SIM1811-03 (SIM0235), an anti-tumor necrosis factor receptor-2 (TNFR2) monoclonal antibody, in patients with advanced solid tumor and/or cutaneous T cell lymphomas (CTCL): Preliminary results from an on-going first-in-human phase I trial in China
Presenter: Furong Liu
Session: Poster session 17